Verve Therapeutics licensed some of the base-editing technology VERVE-101 is based on from Beam Therapeutics. In October, Verve's collaboration partner, Eli Lilly, handed Beam $250 million upfront ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Shares of Verve Therapeutics (VERV-2.53%) sank as much as 30.7% this week, according to data from S&P Global Market Intelligence.The gene-editing company focused on the cardiovascular market ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday. For a relatively new stock (it ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company focused on revolutionizing the treatment of cardiovascular disease through innovative gene-editing approaches.

Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is a Boston, Mass., based biotech that IPO'd in June 2021, raising ~$307m via the issuance of 16.1m shares priced at $19 per share.

Why Verve Therapeutics stock tanked. There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.